Genocea Biosciences Inc Kiemelkedően
Mi az Genocea Biosciences Inc Kiemelkedően?
A Kiemelkedően az Genocea Biosciences Inc - 58.784M
Mi a Kiemelkedően meghatározása?
A fennálló részvények egy olyan vállalat vagy pénzügyi eszköz részvényei, amelyeket a befektetők engedélyeztek, bocsátottak ki és vásároltak meg.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Kiemelkedően a Health Care szektor a NASDAQ-on cégekben a Genocea Biosciences Inc -hoz képest
Mit csinál Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
kiemelkedően -hoz hasonló cégek Genocea Biosciences Inc
- IOL Chemicals and Pharmaceuticals nak Kiemelkedően 58.706M van
- IOL Chemicals and Pharmaceuticals nak Kiemelkedően 58.706M van
- Invesco Asia Trust Plc nak Kiemelkedően 58.707M van
- Cyon Exploration nak Kiemelkedően 58.725M van
- Teleperformance SE nak Kiemelkedően 58.733M van
- Clifton Mining Co nak Kiemelkedően 58.771M van
- Genocea Biosciences Inc nak Kiemelkedően 58.784M van
- Jiulian Resources nak Kiemelkedően 58.787M van
- B.C. Power Controls nak Kiemelkedően 58.800M van
- B.C. Power Controls nak Kiemelkedően 58.800M van
- Iliad SA nak Kiemelkedően 58.818M van
- GTT Communications Inc nak Kiemelkedően 58.820M van
- California Water Service nak Kiemelkedően 58.825M van